Category,FY,Funding IC,Project Number,Sub Project #,Project Title,PI Name,Org Name,State / Country,Amount
Ovarian Cancer,2017,NCI,5R01CA178535-05,,The contribution of rare alleles to ovarian cancer in the population,"GAYTHER, SIMON",CEDARS-SINAI MEDICAL CENTER,CA,"$549,009"
Ovarian Cancer,2017,NCI,5U01CA194393-03,,Quantifying and Characterizing the shared genetic contribution to common cancers,"LINDSTROEM, SARA",UNIVERSITY OF WASHINGTON,WA,"$566,464"
Ovarian Cancer,2017,NIGMS,2P20GM103625-06,5373,Dysbiosis-induced impairment of tumoral leukocyte extravasation,"DINGS, RUUD",UNIV OF ARKANSAS FOR MED SCIS,AR,"$283,100"
Ovarian Cancer,2017,NCI,1K22CA207602-01,,The role of short-form Ron (sfRon) kinase in the pathogenesis of high-grade serous ovarian cancer,"BIENIASZ, MAGDALENA",OKLAHOMA MEDICAL RESEARCH FOUNDATION,OK,"$159,705"
Ovarian Cancer,2017,OD,1R56CA198492-01A1,,Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance,"AMIJI, MANSOOR",NORTHEASTERN UNIVERSITY,MA,"$299,852"
Ovarian Cancer,2017,NIAID,5R01AI109008-05,,Origin of the innate immunity suppression caused by nairovirus' protease activity,"PEGAN, SCOTT",UNIVERSITY OF GEORGIA,GA,"$308,767"
Ovarian Cancer,2017,NIAID,5R01AI033993-23,,Processed Antigen Characterization by Mass Spectrometry,"HUNT, DONALD",UNIVERSITY OF VIRGINIA,VA,"$615,162"
Ovarian Cancer,2017,NCI,5R01CA043054-30,,Nuclear Function of Abl in DNA Damage Response,"WANG, JEAN",UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,"$387,500"
Ovarian Cancer,2017,NIBIB,5R01EB019458-03,,Pre-clinical quantitation of ovarian cancer tumor burden using Magnetic Particle Imaging and non-dilutive cell labeling,"CONOLLY, STEVEN",UNIVERSITY OF CALIFORNIA BERKELEY,CA,"$477,914"
Ovarian Cancer,2017,NCI,5R01CA194498-02,,CDK12 in Ovarian Cancer,"KARNITZ, LARRY",MAYO CLINIC ROCHESTER,MN,"$393,220"
Ovarian Cancer,2017,NCI,5R01CA202919-02,,Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer,"ZHANG, RUGANG",WISTAR INSTITUTE,PA,"$434,625"
Ovarian Cancer,2017,NCI,5R01CA193511-02,,NOX4 mediates oxidative stress in ovarian tumor growth and treatment response,"JIANG, BINGHUA",THOMAS JEFFERSON UNIVERSITY,PA,"$356,850"
Ovarian Cancer,2017,NCI,5R01CA194064-03,,Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy,"MING, XIN",WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,"$283,650"
Ovarian Cancer,2017,NCI,5R03CA191527-02,,Deletion of Arid1a and Kras as a Model of Endometriosis-Associated Ovarian Cancer,"HAWKINS, SHANNON",INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,IN,"$84,148"
Ovarian Cancer,2017,NCI,5R01CA202846-02,,Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles,"YANG, LILY",EMORY UNIVERSITY,GA,"$411,268"
Ovarian Cancer,2017,NCI,5R21CA194965-02,,Evolving Model of Cancer Susceptibility Testing: Clinical Decisions & Outcomes,"SCHWARTZ, MARC",GEORGETOWN UNIVERSITY,DC,"$169,106"
Ovarian Cancer,2017,NCI,5R01CA136494-09,,Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle,"MUKHERJEE, PRIYABRATA",UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,"$304,695"
Ovarian Cancer,2017,NCI,5R01CA190498-03,,gp130 as a novel therapeutic target in ovarian cancer,"NEAMATI, NOURI",UNIVERSITY OF MICHIGAN,MI,"$376,320"
Ovarian Cancer,2017,NCI,5R01CA136512-07,,BRCA1 Function in Post-Damage Nuclear Foci,"LIVINGSTON, DAVID",DANA-FARBER CANCER INST,MA,"$515,452"
Ovarian Cancer,2017,NCI,5R01CA174470-26,,Stimulation of Tumorigenesis by NKG2D,"SPIES, THOMAS",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$568,459"
Ovarian Cancer,2017,NCI,5R01CA172743-05,,Impact of BRCA Testing on Newly Diagnosed U.S. Breast Cancer Patients,"SUTPHEN, REBECCA",UNIVERSITY OF SOUTH FLORIDA,FL,"$678,656"
Ovarian Cancer,2017,NCI,5R01CA186700-03,,Study of biomarkers in ovarian cancer: modulation by activity & diet intervention,"THOMSON, CYNTHIA",UNIVERSITY OF ARIZONA,AZ,"$630,790"
Ovarian Cancer,2017,NCI,5R01CA119171-10,,Nutrition and Physical Activity Assessment Study (NPAAS),"NEUHOUSER, MARIAN",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$799,090"
Ovarian Cancer,2017,NCI,5R01CA047135-27,,Merging Marine-Derived Cytotoxic Natural Products With Experimental Therapeutics,"CREWS, PHIL",UNIVERSITY OF CALIFORNIA SANTA CRUZ,CA,"$636,410"
Ovarian Cancer,2017,NCI,5R01CA203348-02,,Blocking NK cell shedding of CD16a to increase cancer cell killing,"WALCHECK, BRUCE",UNIVERSITY OF MINNESOTA,MN,"$444,991"
Ovarian Cancer,2017,NCI,5R01CA109298-13,,Ovarian Cancer: Mechanisms of Neuroendocrine Regulation,"SOOD, ANIL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$356,980"
Ovarian Cancer,2017,NCI,5R01CA196631-02,,A network platform to connect drug response and prognosis phenotypes for cancers,"LI, HU",MAYO CLINIC ROCHESTER,MN,"$395,911"
Ovarian Cancer,2017,NCI,5R01CA184088-03,,Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy,"KABANOV, ALEXANDER",UNIV OF NORTH CAROLINA CHAPEL HILL,NC,"$344,549"
Ovarian Cancer,2017,NCI,5R00CA179137-04,,"Understanding the origin,initiation,and progression of high-grade serous ovarian cancer","KIM, JAEYEON",INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,IN,"$245,221"
Ovarian Cancer,2017,NCI,5UM1CA173642-05,,Women's Health Initiative Cancer Survivor Cohort,"ANDERSON, GARNET",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$2,260,718"
Ovarian Cancer,2017,NCI,1R01CA211016-01,,Immune Impact on Cancer Chemoresistance,"ZOU, WEIPING",UNIVERSITY OF MICHIGAN,MI,"$609,903"
Ovarian Cancer,2017,NIGMS,5R01GM113940-04,,NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers,"YOU, YOUNGJAE",UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,"$303,400"
Ovarian Cancer,2017,NCI,5R01CA135650-08,,Predictive Cancer Diagnostics and Therapy Response,"MOORE, ANNA",MASSACHUSETTS GENERAL HOSPITAL,MA,"$552,368"
Ovarian Cancer,2017,NCI,2P30CA044579-26,5844,Women's Oncology Program - WON,"SHUPNIK, MARGARET",UNIVERSITY OF VIRGINIA,VA,"$52,177"
Ovarian Cancer,2017,NCI,5R35CA197605-02,,Mucins and immune cell interactions in ovarian cancer pathogenesis & progression,"CRAMER, DANIEL",BRIGHAM AND WOMEN'S HOSPITAL,MA,"$1,031,346"
Ovarian Cancer,2017,NCI,1R01CA211175-01,,Averting recurrent and resistant ovarian tumors,"WANG, QIEN",OHIO STATE UNIVERSITY,OH,"$454,502"
Ovarian Cancer,2017,NCI,5R21CA181994-02,,Targeted Molecular Imaging of Cell Death in Ovarian Cancer,"MILLWARD, STEVEN",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$208,800"
Ovarian Cancer,2017,NCI,5R01CA190423-03,,Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer,"KAUFMANN, SCOTT",MAYO CLINIC ROCHESTER,MN,"$382,326"
Ovarian Cancer,2017,NCI,1R01CA211625-01,,Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors,"KINNEY, ANITA",UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,"$629,227"
Ovarian Cancer,2017,NCI,1R01CA211707-01,,Functional Effects of Ovarian Cancer Risk Variants,"GAYTHER, SIMON",CEDARS-SINAI MEDICAL CENTER,CA,"$686,463"
Ovarian Cancer,2017,NCI,1R01CA211932-01,,Molecularly-Targeted Ultrasound in Ovarian Cancer,"LUTZ, AMELIE",STANFORD UNIVERSITY,CA,"$484,088"
Ovarian Cancer,2017,NCI,5R01CA190176-03,,Effector T Cell Trafficking in Ovarian Cancer,"ZOU, WEIPING",UNIVERSITY OF MICHIGAN,MI,"$513,972"
Ovarian Cancer,2017,NCI,5R03CA194643-02,,Communicate and LEarn About youR Variant of Uncertain Significance (CLEAR VUS),"SCHERR, COURTNEY",NORTHWESTERN UNIVERSITY,IL,"$83,085"
Ovarian Cancer,2017,NCI,5R01CA193249-02,,Behavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance,"LUTGENDORF, SUSAN",UNIVERSITY OF IOWA,IA,"$621,318"
Ovarian Cancer,2017,NHLBI,1R34HL135226-01,,Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer,"ZWICKER, JEFFREY",BETH ISRAEL DEACONESS MEDICAL CENTER,MA,"$165,109"
Ovarian Cancer,2017,NCI,1R03CA212127-01,,The role of X chromosome inactivation in ovarian cancer,"WINHAM, STACEY",MAYO CLINIC ROCHESTER,MN,"$79,500"
Ovarian Cancer,2017,NCI,5R01CA169200-05,,The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer,"BIRRER, MICHAEL",MASSACHUSETTS GENERAL HOSPITAL,MA,"$372,320"
Ovarian Cancer,2017,NCI,5R01CA172667-05,,Annotating the Role of Dysregulated Inositol Phosphate Metabolism in Malignant Ca,"NOMURA, DANIEL",UNIVERSITY OF CALIFORNIA BERKELEY,CA,"$334,984"
Ovarian Cancer,2017,NCCIH,5R01AT008824-02,,Botanical derived progestins and their impact on women's health,"BURDETTE, JOANNA",UNIVERSITY OF ILLINOIS AT CHICAGO,IL,"$359,775"
Ovarian Cancer,2017,NCI,5R01CA174904-05,,Roles of Chromatin Modification in BRCA1 Dependent DNA Repair,"GREENBERG, ROGER",UNIVERSITY OF PENNSYLVANIA,PA,"$332,000"
Ovarian Cancer,2017,NCI,5R00CA175292-04,,Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic Platforms,"RIZVI, IMRAN",MASSACHUSETTS GENERAL HOSPITAL,MA,"$249,000"
Ovarian Cancer,2017,NCI,5R01CA200231-03,,PHARMACOLOGICAL MODULATION OF POLY(ADP-RIBOSE) METABOLISM,"TAINER, JOHN",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$345,984"
Ovarian Cancer,2017,NCI,5R01CA142698-08,,Molecular mechanism and relevance of microRNAs in DSB repair pathway choice,"CHOWDHURY, DIPANJAN",DANA-FARBER CANCER INST,MA,"$409,002"
Ovarian Cancer,2017,NCI,5K99CA197487-02,,Role of DEAD-box helicase in microRNA biogenesis and Cancer,"HAN, CECIL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$101,631"
Ovarian Cancer,2017,NCI,1R01CA203810-01A1,,Using microfluidic single cell culture to characterize cancer cell asymmetric division,"BUCKANOVICH, RONALD",UNIVERSITY OF MICHIGAN,MI,"$433,051"
Ovarian Cancer,2017,NCI,5R01CA138835-08,,The RAP80-BRCC36 Deubiquitinating Complex in DNA Repair,"GREENBERG, ROGER",UNIVERSITY OF PENNSYLVANIA,PA,"$317,509"
Ovarian Cancer,2017,NCI,5R01CA204119-02,,Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI,"GENKINGER, JEANINE",COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,"$572,330"
Ovarian Cancer,2017,NCI,5F31CA203039-02,,Design and synthesis of stabilized pironetin analogs for the treatment of resistant ovarian cancers,"COULUP, SARA",UNIVERSITY OF MINNESOTA,MN,"$29,795"
Ovarian Cancer,2017,NCI,5U10CA180860-04,,Integrated Translational Genoproteomics Center at Washington University,"MUTCH, DAVID",WASHINGTON UNIVERSITY,MO,"$540,405"
Ovarian Cancer,2017,NCI,5R01CA095175-13,,Analysis of BRCA1 Recombination Functions,"SCULLY, RALPH",BETH ISRAEL DEACONESS MEDICAL CENTER,MA,"$328,700"
Ovarian Cancer,2017,NCI,5R01CA183040-04,,Ovarian cancer gene therapy using HPV pseudovirion,"WU, TZYY-CHOOU",JOHNS HOPKINS UNIVERSITY,MD,"$336,150"
Ovarian Cancer,2017,NCI,5R21CA198263-02,,Cbx-3/HP-1gamma deficiency confers anti-tumor immunity,"THAI, TO-HA",BETH ISRAEL DEACONESS MEDICAL CENTER,MA,"$225,765"
Ovarian Cancer,2017,NCI,5R21CA205819-02,,Modeling the impact of mutations in ubiquitin ligase genes on transcriptional programs in endometrial cancer,"LESLIE, CHRISTINA",SLOAN-KETTERING INST CAN RESEARCH,NY,"$186,398"
Ovarian Cancer,2017,NCI,5R01CA169604-05,,Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss,"LENGYEL, ERNST",UNIVERSITY OF CHICAGO,IL,"$327,850"
Ovarian Cancer,2017,NCI,5U01CA200469-02,,Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer,"ZHANG, ZHEN",JOHNS HOPKINS UNIVERSITY,MD,"$441,524"
Ovarian Cancer,2017,NCI,5R01CA175318-03,,A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer,"HATEFI, ARASH","RUTGERS, THE STATE UNIV OF N.J.",NJ,"$354,563"
Ovarian Cancer,2017,NCI,5R01CA203971-02,,Deubiquitinases in regulation of BRCA1 pathway,"YUAN, JIAN",MAYO CLINIC ROCHESTER,MN,"$363,713"
Ovarian Cancer,2017,NCI,5R01CA182832-04,,An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer,"MATEI, DANIELA",NORTHWESTERN UNIVERSITY AT CHICAGO,IL,"$323,044"
Ovarian Cancer,2017,NCI,5R01CA181543-04,,Analysis of Intratumoral Crosstalk in Clonal Populations of OvarianTumor Cells,"BRUGGE, JOAN",HARVARD MEDICAL SCHOOL,MA,"$395,654"
Ovarian Cancer,2017,NCI,5R01CA197780-02,,Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer,"DIFEO, ANALISA",CASE WESTERN RESERVE UNIVERSITY,OH,"$363,581"
Ovarian Cancer,2017,NCI,5R21CA191243-02,,Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid,"SULCHEK, TODD",GEORGIA INSTITUTE OF TECHNOLOGY,GA,"$187,018"
Ovarian Cancer,2017,NLM,5K01LM012100-03,,Informatic Methods for Differential Signaling and Immune Co-Regulatory Expression,"ENG, KEVIN",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$166,765"
Ovarian Cancer,2017,NCI,5R03CA191543-02,,Enhancing at-Risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer,"HURTADO DE MENDOZA CASAUS, ALEJANDRA",GEORGETOWN UNIVERSITY,DC,"$79,150"
Ovarian Cancer,2017,NCI,1R43CA213632-01,,"""Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer""","WOLFSON, ALEXEY","ADVANCED RNA TECHNOLOGIES, LLC",CO,"$231,500"
Ovarian Cancer,2017,NCI,1F30CA213737-01,,A Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer,"MCGEHEE, CORDELIA",MAYO CLINIC ROCHESTER,MN,"$44,244"
Ovarian Cancer,2017,NCI,5R01CA184502-04,,(PQD5) Avatar-directed Treatment for Ovarian Cancer,"WEROHA, SARAVUT",MAYO CLINIC ROCHESTER,MN,"$714,297"
Ovarian Cancer,2017,NCI,5R01CA182413-03,,Origins of Ovarian Carcinoma,"NIKITIN, ALEXANDER",CORNELL UNIVERSITY,NY,"$358,780"
Ovarian Cancer,2017,NIBIB,1F32EB023101-01A1,,Sequence- and Stereocontrolled Triazolium-containing Precise Polymers for siRNA Complexation and Delivery,"GOLDER, MATTHEW",MASSACHUSETTS INSTITUTE OF TECHNOLOGY,MA,"$56,694"
Ovarian Cancer,2017,NCI,5R01CA115483-13,,Therapeutic Targeting Agents for Ovarian Cancer,"LAM, KIT",UNIVERSITY OF CALIFORNIA AT DAVIS,CA,"$345,660"
Ovarian Cancer,2017,NCI,1U01CA213759-01,,Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling,"LOPEZ-BERESTEIN, GABRIEL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$515,198"
Ovarian Cancer,2017,NCI,5R01CA197784-02,,Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients,"PASICK, RENA","UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,"$751,892"
Ovarian Cancer,2017,NCI,5R01CA196619-02,,Credentialing Ovarian Cancer Models in the Context of the Dualistic Pathway Paradigm,"CHO, KATHLEEN",UNIVERSITY OF MICHIGAN,MI,"$489,123"
Ovarian Cancer,2017,NIMHD,5R01MD009697-02,,Spatiotemporal Analysis of Disparities in Ovarian Cancer Treatment and Survival,"BRISTOW, ROBERT",UNIVERSITY OF CALIFORNIA-IRVINE,CA,"$386,250"
Ovarian Cancer,2017,NCI,5R01CA184968-04,,(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers,"SIKIC, BRANIMIR",STANFORD UNIVERSITY,CA,"$509,161"
Ovarian Cancer,2017,NCI,5U01CA152990-07,,"Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery","SKATES, STEVEN",MASSACHUSETTS GENERAL HOSPITAL,MA,"$1,356,082"
Ovarian Cancer,2017,NCI,5R01CA206561-02,,Quantitative assessment of the role of collagen alterations in ovarian cancer,"CAMPAGNOLA, PAUL",UNIVERSITY OF WISCONSIN-MADISON,WI,"$418,598"
Ovarian Cancer,2017,NIGMS,5SC1CA199810-03,,Novel Nanotechnology Platform for Breast Cancer Treatment,"AKALA, EMMANUEL",HOWARD UNIVERSITY,DC,"$27,280"
Ovarian Cancer,2017,NCI,5R01CA180769-09,,Signaling Connections Controlling Cell Motility and Invasion,"SCHLAEPFER, DAVID",UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,"$376,500"
Ovarian Cancer,2017,NCI,5R21CA205322-02,,Multiplexed exosome analyses with DNA barcoding,"LEE, HAKHO",MASSACHUSETTS GENERAL HOSPITAL,MA,"$199,856"
Ovarian Cancer,2017,NCI,5R01CA197976-02,,The Hippo/YAP Signaling Pathway in Ovarian High Grade Serous Carcinoma,"WANG, CHENG",UNIVERSITY OF NEBRASKA MEDICAL CENTER,NE,"$53,746"
Ovarian Cancer,2017,NIGMS,5R35GM118026-02,,Mechanisms of Genome Integrity,"GREENE, ERIC",COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,"$537,987"
Ovarian Cancer,2017,NCI,5R01CA175480-05,,Tumor-targeted Polymersomes to image and Treat Ovarian Cancer,"CHENG, ZHILIANG",UNIVERSITY OF PENNSYLVANIA,PA,"$327,536"
Ovarian Cancer,2017,NCI,5R01CA132755-10,,Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis,"YU, XIAOCHUN",BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,"$382,500"
Ovarian Cancer,2017,NIGMS,5R35GM118175-02,,Homologous recombination mechanisms in mammalian cells,"JASIN, MARIA",SLOAN-KETTERING INST CAN RESEARCH,NY,"$531,434"
Ovarian Cancer,2017,NCI,5U01CA200462-02,,MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer,"BAST, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$889,216"
Ovarian Cancer,2017,NCI,5U01CA152637-07,,"Breast, Colorectal, and Ovary Cancer Clinical Validation Center","LI, CHRISTOPHER",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$972,870"
Ovarian Cancer,2017,NCI,1U01CA214114-01,,Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit,"PAULOVICH, AMANDA",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$1,507,572"
Ovarian Cancer,2017,NCI,5F32CA196008-03,,Elucidation of the impact of commonly co-altered genes on chemosensitivity using a novel model of high-grade serous ovarian cancer,"CHEN, HSING-YU",HARVARD MEDICAL SCHOOL,MA,"$17,460"
Ovarian Cancer,2017,OD,1S10OD023508-01,,Pre-Clinical 7T MRI for Oklahoma,"TOWNER, RHEAL",OKLAHOMA MEDICAL RESEARCH FOUNDATION,OK,"$600,000"
Ovarian Cancer,2017,OD,1S10OD021669-01A1,,Purchase of a PerkinElmer IVIS SpectrumCT Imaging System,"LIEBERMAN, PAUL",WISTAR INSTITUTE,PA,"$579,346"
Ovarian Cancer,2017,OD,1S10OD023658-01,,Purchase of a Seahorse Bioscience XF Analyzer,"MURPHY, MAUREEN",WISTAR INSTITUTE,PA,"$188,255"
Ovarian Cancer,2017,NCI,5R01CA172272-05,,The BARD1 tumor suppressor and breast cancer,"BAER, RICHARD",COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,"$332,000"
Ovarian Cancer,2017,NCI,5R01CA195670-03,,The Tumor Suppressor Role of SMARCA4 in SCCOHT,"WEISSMAN, BERNARD",UNIV OF NORTH CAROLINA CHAPEL HILL,NC,"$718,667"
Ovarian Cancer,2017,NCI,5K07CA201013-02,,Health Services Career Development: Improving Medical Decisions in Ovarian Cancer,"MEYER, LARISSA",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$170,506"
Ovarian Cancer,2017,NCI,5R01CA176166-04,,Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer,"CANTOR, SHARON",UNIV OF MASSACHUSETTS MED SCH WORCESTER,MA,"$347,563"
Ovarian Cancer,2017,NCI,1R01CA200507-01A1,,Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers,"GALANIS, EVANTHIA",MAYO CLINIC ROCHESTER,MN,"$509,698"
Ovarian Cancer,2017,NCI,5R01CA177909-05,,Platelets promote growth of ovarian cancer,"AFSHAR-KHARGHAN, VAHID",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$332,000"
Ovarian Cancer,2017,NCI,2P30CA006973-54,8090,Breast and Ovarian Cancer Program - 08,"STEARNS, VERED",JOHNS HOPKINS UNIVERSITY,MD,"$36,867"
Ovarian Cancer,2017,NIGMS,1SC2GM122686-01,,Targeted Promoter Demethylation in Ovarian Cancer Cells,"SUNG, CHANG",TEXAS A&M UNIVERSITY-KINGSVILLE,TX,"$137,999"
Ovarian Cancer,2017,NCI,5R01CA193965-02,,Redefining Normal: personalized CA125 cutpoints for ovarian cancer screening,"TERRY, KATHRYN",BRIGHAM AND WOMEN'S HOSPITAL,MA,"$394,683"
Ovarian Cancer,2017,NCI,5R01CA155025-07,,The role of a BRCA1 associated complex in DNA damage response and tumor suppression,"WANG, BIN",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$380,000"
Ovarian Cancer,2017,NCI,5K12CA090628-17,,Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic,"JATOI, AMINAH",MAYO CLINIC ROCHESTER,MN,"$810,000"
Ovarian Cancer,2017,NCI,5R01CA178687-06,,Effects of Common Polymorphisms in Immune Sensors in Tumor Immunosurveillance,"CONEJO-GARCIA, JOSE",H. LEE MOFFITT CANCER CTR & RES INST,FL,"$356,900"
Ovarian Cancer,2017,NCI,5R01CA193136-03,,MDSCs in Ovarian Cancer,"ZOU, WEIPING",UNIVERSITY OF MICHIGAN,MI,"$498,257"
Ovarian Cancer,2017,NCI,5R01CA166907-05,,Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity,"RAMKUMAR, VICKRAM",SOUTHERN ILLINOIS UNIVERSITY SCH OF MED,IL,"$301,907"
Ovarian Cancer,2017,NICHD,5R01HD083930-02,,Cryopreservation and Transplantation of Ovarian Cortical Tissue for Fertility Preservation,"ZELINSKI, MARY",OREGON HEALTH & SCIENCE UNIVERSITY,OR,"$627,191"
Ovarian Cancer,2017,NCI,1R01CA214545-01,,Targeting Kinesin Family Member 15 for the Treatment of Cancer,"GODWIN, ANDREW",UNIVERSITY OF KANSAS MEDICAL CENTER,KS,"$641,589"
Ovarian Cancer,2017,NCI,1R01CA215587-01,,Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO,"EPPERSON, C. NEILL",UNIVERSITY OF PENNSYLVANIA,PA,"$548,965"
Ovarian Cancer,2017,NCI,1R01CA214567-01,,Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy,"LARSEN, SCOTT",UNIVERSITY OF MICHIGAN,MI,"$636,181"
Ovarian Cancer,2017,NCI,1R01CA215483-01,,Experimental Therapeutics by targeting Spleen Tyrosine Kinase,"SHIH, IE-MING",JOHNS HOPKINS UNIVERSITY,MD,"$374,208"
Ovarian Cancer,2017,NCI,5R01CA176078-04,,Dissecting the role of STAT3 and targeting ovarian cancer,"KARUPPAIYAH, SELVENDIRAN",OHIO STATE UNIVERSITY,OH,"$320,524"
Ovarian Cancer,2017,NCI,5R01CA188571-03,,"DYRK1A signaling in control of cell growth, proliferation and DNA damage repair","LITOVCHICK, LARISA",VIRGINIA COMMONWEALTH UNIVERSITY,VA,"$341,494"
Ovarian Cancer,2017,NCI,5R21CA202745-02,,Dim light at night alters pancreatic cell signaling and predisposes to pancreatic adenocarcinoma,"NELSON, RANDY",OHIO STATE UNIVERSITY,OH,"$167,475"
Ovarian Cancer,2017,NCI,5R01CA199004-03,,Targeting the vascularity for delivery of inhibitors of metastasis in ovarian cancer,"MOR, GIL",YALE UNIVERSITY,CT,"$511,177"
Ovarian Cancer,2017,NCI,5R01CA188900-03,,Novel immunological biomarkers ovarian cancer prognosis,"SEGAL, BRAHM",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$646,389"
Ovarian Cancer,2017,NCI,5U01CA116167-10,,BRCA1 and BRCA2 missense mutations and breast cancer risk,"COUCH, FERGUS",MAYO CLINIC ROCHESTER,MN,"$527,128"
Ovarian Cancer,2017,NCI,5R01CA157664-08,,Initiation and Evolution of the Ovarian Cancer Microenvironment,"CONEJO-GARCIA, JOSE",H. LEE MOFFITT CANCER CTR & RES INST,FL,"$372,820"
Ovarian Cancer,2017,NCI,5R01CA204019-02,,Multiplexed analysis of exosomes in cancer nano therapy,"WEISSLEDER, RALPH",MASSACHUSETTS GENERAL HOSPITAL,MA,"$389,111"
Ovarian Cancer,2017,NCI,1R21CA210210-01A1,,Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors,"KHABELE, DINEO",UNIVERSITY OF KANSAS MEDICAL CENTER,KS,"$182,020"
Ovarian Cancer,2017,NCI,1R01CA209818-01A1,,Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer,"MINKO, TAMARA","RUTGERS, THE STATE UNIV OF N.J.",NJ,"$470,010"
Ovarian Cancer,2017,NIBIB,1R21EB024101-01,,Microfluidic Integrative Circulating miRNA Profiling for Cancer Diagnosis,"ZENG, YONG",UNIVERSITY OF KANSAS LAWRENCE,KS,"$230,605"
Ovarian Cancer,2017,NCI,5R01CA131582-08,,Identification of Ovarian Cancer Plasma Biomarkers,"SPEICHER, DAVID",WISTAR INSTITUTE,PA,"$452,569"
Ovarian Cancer,2017,NCI,5R00CA184043-05,,Targeting Ovarian Cancer via Cooperative Oncogene Interactions,"HARGREAVES, DIANA",SALK INSTITUTE FOR BIOLOGICAL STUDIES,CA,"$249,000"
Ovarian Cancer,2017,NCI,5R01CA184717-04,,The Regulation of Cisplatin resistance in ovarian cancer,"ZHU, WENGE",GEORGE WASHINGTON UNIVERSITY,DC,"$328,888"
Ovarian Cancer,2017,NCI,5R01CA188251-04,,Molecular Insights into the Fanconi Anemia Tumor Suppressor Signaling Pathway,"FEI, PEIWEN",UNIVERSITY OF HAWAII AT MANOA,HI,"$319,550"
Ovarian Cancer,2017,NCI,5R01CA207034-02,,Mechanism of evasion by ovarian cancers from anti-VEGF therapy,"NAORA, HONAMI",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$366,000"
Ovarian Cancer,2017,NCI,5K22CA193860-02,,"PCOS, Type II diabetes and ovarian cancer risk","HARRIS, HOLLY",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$184,615"
Ovarian Cancer,2017,NCI,5R01CA197359-03,,Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy,"BERLIN, JACOB",BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,"$388,875"
Ovarian Cancer,2017,NCI,1R01CA207260-01A1,,Exploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortium,"SCHILDKRAUT, JOELLEN",UNIVERSITY OF VIRGINIA,VA,"$700,701"
Ovarian Cancer,2017,NCI,1R01CA215797-01,,Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors,"DANNENBERG, ANDREW",WEILL MEDICAL COLL OF CORNELL UNIV,NY,"$515,275"
Ovarian Cancer,2017,NCI,5R01CA193578-03,,Tunable Microchip Sorting of BRCA1 Nuclear Assemblies,"KELLY, DEBORAH",VIRGINIA POLYTECHNIC INST AND ST UNIV,VA,"$358,506"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5590,"Inhibition of indole-amine 2,3 dioxygenase to Enhance Ovarian Tumor Immunity","ODUNSI, KUNLE",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$571,869"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5591,Rapamycin and IL-21 Conditioned CD8+ T Cells for Adoptive Cellular Therapy of Ov,"SHRIKANT, PROTUL",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$605,749"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5593,MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1,"KALINSKI, PAWEL",UNIVERSITY OF PITTSBURGH,PA,"$639,310"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5595,Administrative Core,"ODUNSI, KUNLE",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$81,606"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5596,Biospecimen Core,"MORRISON, CARL",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$81,190"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5597,Biostatistics/Medical Informatics,"HUTSON, ALAN",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$66,966"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5598,Immune Monitoring Core,"WALLACE, PAUL",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$106,356"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5599,Developmental Research Program,"MOYSICH, KIRSTEN",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$76,662"
Ovarian Cancer,2017,NCI,5P50CA159981-05,5600,Career Development Program,"LELE, SHASHIKANT",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$70,292"
Ovarian Cancer,2017,NHLBI,1R01HL132251-01A1,,The Roles and Regulation of BRCA1 in Hematopoiesis,"ROSS, THEODORA",UT SOUTHWESTERN MEDICAL CENTER,TX,"$405,000"
Ovarian Cancer,2017,NCI,5R01CA190237-03,,Targeting BRCA Deficient Cells for Killing,"POMERANTZ, RICHARD",TEMPLE UNIV OF THE COMMONWEALTH,PA,"$356,850"
Ovarian Cancer,2017,NCI,1R01CA216234-01,,Role of microbiota in therapy to ovarian cancer,"RANDALL, TROY",UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,"$426,139"
Ovarian Cancer,2017,NCI,1R03CA216127-01,,A New Ovarian Cancer Mouse Model Based on Nanoparticle Gene Delivery,"YANG, YANG",YALE UNIVERSITY,CT,"$77,000"
Ovarian Cancer,2017,NCI,1R01CA207407-01A1,,Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers,"STEPHAN, MATTHIAS",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$371,925"
Ovarian Cancer,2017,NCI,1R03CA208573-01A1,,Metformin Supplementation for Ovarian Cancer Prevention: A Prospective Preclinical Study,"RAMACHANDRAN, RAMESH",PENNSYLVANIA STATE UNIVERSITY-UNIV PARK,PA,"$78,600"
Ovarian Cancer,2017,NCI,1R03CA208494-01A1,,Development of Cell-based Functional Tests for Rare Germline ATM Gene Variants in Hereditary Ovarian Cancer Families,"TAINSKY, MICHAEL",WAYNE STATE UNIVERSITY,MI,"$77,000"
Ovarian Cancer,2017,NCI,5F30CA203095-02,,Transcriptomic profiling and functional characterization of fusion genes in recurrent ovarian cancer,"PRIEDIGKEIT, NOLAN",UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,"$49,044"
Ovarian Cancer,2017,NCI,5K12CA076930-17,,Career Development in Pediatric and Medical Oncology,"BERNSTEIN, IRWIN",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$701,719"
Ovarian Cancer,2017,NCI,1R01CA208244-01A1,,Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP,"CHOWDHURY, DIPANJAN",DANA-FARBER CANCER INST,MA,"$385,557"
Ovarian Cancer,2017,NCI,1R21CA204036-01A1,,In vivo anti-PD1 gene therapy,"LIEBER, ANDRE",UNIVERSITY OF WASHINGTON,WA,"$202,112"
Ovarian Cancer,2017,NCI,5R35CA197458-03,,GENOMIC ANALYSIS OF INHERITED BREAST AND OVARIAN CANCER,"KING, MARY-CLAIRE",UNIVERSITY OF WASHINGTON,WA,"$927,000"
Ovarian Cancer,2017,NCI,1K99CA207729-01A1,,Copy Number Alterations in Low Mutation Cancer,"DELANEY, JOE",UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,"$118,896"
Ovarian Cancer,2017,NIGMS,2R01GM097272-06A1,,Cellular responses to DNA replication stress,"SMOLKA, MARCUS",CORNELL UNIVERSITY,NY,"$332,001"
Ovarian Cancer,2017,NCI,5R01CA210370-02,,Early detection of ovarian cancer by serum marker and targeted ultrasound imaging,"BARUA, ANIMESH",RUSH UNIVERSITY MEDICAL CENTER,IL,"$356,180"
Ovarian Cancer,2017,NCI,5F30CA192648-03,,Deciphering Links Between Inflammation and Cancer with IMP-1 Inhibitors,"MAHAPATRA, LILY",UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,IL,"$49,044"
Ovarian Cancer,2017,NCI,5R01CA196200-03,,Ovarian Cancer Chemoprevention,"BENBROOK, DORIS",UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,"$500,225"
Ovarian Cancer,2017,NCI,5K07CA166210-05,,Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer,"WRIGHT, ALEXI",DANA-FARBER CANCER INST,MA,"$177,120"
Ovarian Cancer,2017,NCI,5R01CA135354-07,,ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer,"BAST, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$380,000"
Ovarian Cancer,2017,NINR,5F31NR015170-03,,Hormone Therapy Decision Making in Older Women,"HUNTER, MARY","UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,"$35,495"
Ovarian Cancer,2017,NCI,5F32CA200357-02,,Role of Follicular Fluid Exosomes on Ovarian/Fallopian Carcinogenesis,"BRACHOVA, PAVLA",UNIVERSITY OF KANSAS MEDICAL CENTER,KS,"$59,166"
Ovarian Cancer,2017,NCI,5P30CA036727-31,5725,Molecular and Biochemical Etiology (MBE),"BAND, HAMID",UNIVERSITY OF NEBRASKA MEDICAL CENTER,NE,"$66,915"
Ovarian Cancer,2017,NCI,5R01CA188943-03,,Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors,"HILDEBRANDT, MICHELLE",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$1,225,214"
Ovarian Cancer,2017,NCI,5R01CA188025-04,,Iron addiction and the biology of ovarian cancer,"TORTI, SUZY",UNIVERSITY OF CONNECTICUT SCH OF MED/DNT,CT,"$334,085"
Ovarian Cancer,2017,NCI,5R21CA209848-02,,Algorithms for Literature-Guided Multi-Platform Identification of Cancer Subtypes,"CHUNG, DONGJUN",MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,"$162,581"
Ovarian Cancer,2017,NCI,5R01CA181663-02,,Mechanisms of radioresistance and strategies for radiosensitization in OCCC,"PENG, GUANG",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,$1
Ovarian Cancer,2017,NCI,5R01CA131407-10,,Re-activating Memory T Cells in the Microenvironment of Human Tumors,"BANKERT, RICHARD",STATE UNIVERSITY OF NEW YORK AT BUFFALO,NY,"$326,466"
Ovarian Cancer,2017,NCI,5K22CA181611-03,,Online monitoring and image-guided treatment of chemoresistant micrometastases,"SPRING, BRYAN",NORTHEASTERN UNIVERSITY,MA,"$186,251"
Ovarian Cancer,2017,RMAP,5R21CA207816-02,,Integrated Digital Microfluidic Platforms for Next-Generation Glycomics,"ZENG, YONG",UNIVERSITY OF KANSAS LAWRENCE,KS,"$292,724"
Ovarian Cancer,2017,NCI,5R01CA187209-04,,Functional analysis of BRCA1 in DNA damage response and tumor suppression,"YU, XIAOCHUN",BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,"$352,750"
Ovarian Cancer,2017,NCI,5R01CA207497-02,,Provectors for treatment of ovarian cancer,"SUH, JUNGHAE",RICE UNIVERSITY,TX,"$352,623"
Ovarian Cancer,2017,NCI,5P30CA047904-29,6390,Breast and Ovarian Cancer Program (Project-007),"LEE, ADRIAN",UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,"$34,500"
Ovarian Cancer,2017,RMAP,5UH3TR000943-05,,Novel extra cellular RNA-based combinatorial RNA inhibition therapy,"SOOD, ANIL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$1,000,000"
Ovarian Cancer,2017,NCI,5SC2CA206194-03,,Theranostic nanoparticles for dual modality cancer therapy,"CZAJKOWSKA, ANETA",BROOKLYN COLLEGE,NY,"$157,000"
Ovarian Cancer,2017,NCI,5R01CA142746-08,,Enzyme-instructed self-assembly for molecular anticancer nanomedicines,"XU, BING",BRANDEIS UNIVERSITY,MA,"$368,145"
Ovarian Cancer,2017,NCI,5R21CA209281-02,,Development of DNA Polymerase Î¸ Inhibitors for Precision Medicine in BRCA Deficient Cancers,"POMERANTZ, RICHARD",TEMPLE UNIV OF THE COMMONWEALTH,PA,"$169,650"
Ovarian Cancer,2017,NCI,5R01CA102310-14,,Role of FAK in Tumorigenesis,"SCHLAEPFER, DAVID",UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,"$331,313"
Ovarian Cancer,2017,NCI,5R00CA184415-04,,Functional Analysis of LncRNAs in Epithelial Ovarian Cancer,"LAWRENSON, KATE",CEDARS-SINAI MEDICAL CENTER,CA,"$227,414"
Ovarian Cancer,2017,NCI,5P01CA087969-18,8092,Core A: Biospecimen and High-Dimensional Data Management Core,"TWOROGER, SHELLEY",BRIGHAM AND WOMEN'S HOSPITAL,MA,"$629,241"
Ovarian Cancer,2017,NCI,5P01CA087969-18,8096,Project 3: Ovarian Cancer,"TWOROGER, SHELLEY",BRIGHAM AND WOMEN'S HOSPITAL,MA,"$326,903"
Ovarian Cancer,2017,NCI,5P01CA087969-18,8097,Project 4: Statistical Innovations,"ROSNER, BERNARD",BRIGHAM AND WOMEN'S HOSPITAL,MA,"$167,985"
Ovarian Cancer,2017,NCI,1F30CA217079-01,,"FemKube, the human female reproductive tract-on-a-chip, as a platform for studying high grade serous ovarian cancer and developing novel cancer chemotherapeutics","YOUNG, ALEXANDRIA",UNIVERSITY OF ILLINOIS AT CHICAGO,IL,"$44,044"
Ovarian Cancer,2017,NCI,5R01CA180710-05,,Targeting nucleotide excision repair in combination cancer therapy,"TURCHI, JOHN",INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,IN,"$323,700"
Ovarian Cancer,2017,NICHD,5R01HD073499-05,,Genetic regulation of ovariole development in Drosophila,"EXTAVOUR, CASSANDRA",HARVARD UNIVERSITY,MA,"$317,348"
Ovarian Cancer,2017,NCI,5R01CA181808-04,,Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis,"RICHARDS, JOANNE",BAYLOR COLLEGE OF MEDICINE,TX,"$336,565"
Ovarian Cancer,2017,NCI,1R01CA211648-01A1,,Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer,"ADLI, MAZHAR",UNIVERSITY OF VIRGINIA,VA,"$429,211"
Ovarian Cancer,2017,NIGMS,5R35GM119512-02,,Connecting BRCA1 functions with DNA crosslink sensitivity,"LONG, DAVID",MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,"$373,750"
Ovarian Cancer,2017,NCI,1R43CA213538-01A1,,Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles,"COLBY, AARON",IONIC PHARMACEUTICALS,MA,"$283,122"
Ovarian Cancer,2017,NCI,5K22CA181550-03,,Targeting defective DNA repair for the prevention of BRCA1-associated cancers,"ALLI, ELIZABETH",WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,"$162,000"
Ovarian Cancer,2017,NCI,5R00CA166228-05,,A Pathway-based approach to investigate oncogenic mechanisms in ovarian cancer,"GATZA, MICHAEL",RBHS -CANCER INSTITUTE OF NEW JERSEY,NJ,"$249,000"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7470,Adminstrative Core,"SPRIGGS, DAVID",SLOAN-KETTERING INST CAN RESEARCH,NY,"$104,237"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7471,Biostatistics Core,"IASONOS, ALEXIA",SLOAN-KETTERING INST CAN RESEARCH,NY,"$81,105"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7472,Pathology Core,"DELAIR, DEBORAH",SLOAN-KETTERING INST CAN RESEARCH,NY,"$104,236"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7473,MUC16 Antibody Based Strategies for Imaging and Therapy,"SPRIGGS, DAVID",SLOAN-KETTERING INST CAN RESEARCH,NY,"$729,636"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7474,Personalized Immunotherapy of Patients with Ovarian Cancer,"SABBATINI, PAUL",SLOAN-KETTERING INST CAN RESEARCH,NY,"$625,397"
Ovarian Cancer,2017,NCI,5P01CA190174-03,7476,Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain,"RAVETCH, JEFFREY",SLOAN-KETTERING INST CAN RESEARCH,NY,"$389,221"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7019,Biospecimens and Patient Registry,"KEENEY, GARY",MAYO CLINIC ROCHESTER,MN,"$134,451"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7020,Core C - Biostatistics Core,"OBERG, ANN",MAYO CLINIC ROCHESTER,MN,"$156,342"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7021,Core D - Animal Models Core,"HALUSKA, PAUL",MAYO CLINIC ROCHESTER,MN,"$149,342"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7022,Administrative Core,"KAUFMANN, SCOTT",MAYO CLINIC ROCHESTER,MN,"$575,779"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7023,Project 1 - PARP Project,"KAUFMANN, SCOTT",MAYO CLINIC ROCHESTER,MN,"$188,670"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7024,Project 6 - PKC Iota,"FIELDS, ALAN",MAYO CLINIC ROCHESTER,MN,"$285,273"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7025,Project 7 - Metformin,"LENGYEL, ERNST",MAYO CLINIC ROCHESTER,MN,"$354,105"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7026,Project 8 - TH17 Dendritic Cell Vaccine,"KNUTSON, KEITH",MAYO CLINIC ROCHESTER,MN,"$306,631"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7027,Developmental Reserach Pilot Projects,"CLIBY, WILLIAM",MAYO CLINIC ROCHESTER,MN,"$99,606"
Ovarian Cancer,2017,NCI,5P50CA136393-08,7028,Career Development,"GOODE, ELLEN",MAYO CLINIC ROCHESTER,MN,"$49,801"
Ovarian Cancer,2017,NCI,5R21CA208610-02,,Pax2 loss in fallopian tube lesions and strategies for restoration in serous cancer,"BURDETTE, JOANNA",UNIVERSITY OF ILLINOIS AT CHICAGO,IL,"$163,017"
Ovarian Cancer,2017,NCI,1R01CA214043-01A1,,Macrophage-based ovarian cancer immunotherapy,"YULL, FIONA",VANDERBILT UNIVERSITY,TN,"$371,717"
Ovarian Cancer,2017,NCI,5F31CA192891-04,,Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer,"PRICE, JESSICA",COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,"$49,044"
Ovarian Cancer,2017,NCI,5U01CA202144-03,,Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics,"ALTER, ORLY",UNIVERSITY OF UTAH,UT,"$704,509"
Ovarian Cancer,2017,NCATS,5R21TR001731-02,,Ketorolac and Related NSAIDs for Targeting Rho-family GTPases in Ovarian Cancer,"WANDINGER-NESS, ANGELA",UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,"$303,000"
Ovarian Cancer,2017,NCI,5R01CA207456-02,,Epidemiology and biology of lncRNAs in ovarian cancer,"SELLERS, THOMAS",H. LEE MOFFITT CANCER CTR & RES INST,FL,"$951,947"
Ovarian Cancer,2017,NCI,5U24CA209999-02,,Monitoring tumor subclonal heterogeneity over time and space,"MARTH, GABOR",UNIVERSITY OF UTAH,UT,"$751,812"
Ovarian Cancer,2017,NCI,5P50CA116201-12,8257,01 Project 1:  Cancer risks for mutations in breast cancer predisposition genes,"COUCH, FERGUS",MAYO CLINIC ROCHESTER,MN,"$494,441"
Ovarian Cancer,2017,NCI,5R44CA203350-03,,Genetic Cytology for Ovarian and Endometrial Cancer Screening,"KINDE, ISAAC","PAPGENE, INC.",MD,"$994,554"
Ovarian Cancer,2017,NCI,5UM1CA182910-05,,Shanghai Womens Health Study,"ZHENG, WEI",VANDERBILT UNIVERSITY MEDICAL CENTER,TN,"$1,321,497"
Ovarian Cancer,2017,NCI,5R01CA208753-02,,Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies,"ORSULIC, SANDRA",CEDARS-SINAI MEDICAL CENTER,CA,"$400,313"
Ovarian Cancer,2017,NCI,1R41CA213479-01A1,,Investigation of antibody-drug conjugates of a novel target,"CUI, JIE","WNTRIX, INC.",TX,"$225,000"
Ovarian Cancer,2017,NCI,5R44CA206606-02,,A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy,"WINRAM, SCOTT","CYNVEC, LLC",NY,"$1,004,186"
Ovarian Cancer,2017,NCATS,1R43TR002043-01,,Reconstituted High Density Lipoprotein Particles as siRNA Carriers,"CHATTERJEE, DEV","FANNIN PARTNERS, LLC",TX,"$324,593"
Ovarian Cancer,2017,NCI,1U54CA209978-01A1,8334,Project 1: Dynamic Genomic and Microenvironmental Models of Acquired Chemoresistance,"BILD, ANDREA",UNIVERSITY OF UTAH,UT,"$434,320"
Ovarian Cancer,2017,NCI,1U54CA209978-01A1,8335,Project 2: Targeting Cooperative Phenotypes Common in Spatial Heterogeneity,"CHANG, JEFFREY",UNIVERSITY OF UTAH,UT,"$331,274"
Ovarian Cancer,2017,NCI,7K08CA211362-02,,Defining the formation and function of carcinoma-associated mesenchymal stem cells in the ovarian cancer microenvironment,"COFFMAN, LAN",UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,"$166,050"
Ovarian Cancer,2017,NIBIB,5R01EB020605-02,,Advanced Salpingoscope for Minimally-Invasive Imaging of the Fallopian Tubes,"BARTON, JENNIFER",UNIVERSITY OF ARIZONA,AZ,"$334,425"
Ovarian Cancer,2017,NCI,5R01CA172404-05,,Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer,"RAMUS, SUSAN",UNIVERSITY OF NEW SOUTH WALES,AUSTRA,"$483,257"
Ovarian Cancer,2017,NIGMS,5R01GM059078-18,,Molecular Probes for Biomembrane Recognition,"SMITH, BRADLEY",UNIVERSITY OF NOTRE DAME,IN,"$376,671"
Ovarian Cancer,2017,NCI,5U24CA210954-02,,"iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC","ZHANG, BING",BAYLOR COLLEGE OF MEDICINE,TX,"$973,045"
Ovarian Cancer,2017,NCI,5R50CA211280-02,,Discovery and Characterization of Mutations in Breast and Ovarian Cancers,"ADAMSON, AARON",BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,"$215,047"
Ovarian Cancer,2017,NCI,5F99CA212222-02,,Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancer,"BARNARD, MOLLIE",HARVARD SCHOOL OF PUBLIC HEALTH,MA,"$31,260"
Ovarian Cancer,2017,NCI,5F99CA212470-02,,FOXM1-RHNO1 Oncogenic Axis in Ovarian Cancer,"BARGER, CARTER",UNIVERSITY OF NEBRASKA MEDICAL CENTER,NE,"$31,739"
Ovarian Cancer,2017,NCI,5F99CA212460-02,,Identifying epigenetic drivers and their targets in aggressive breast and ovarian cancers,"SAHNI (BRANCATO), JENNIFER",CASE WESTERN RESERVE UNIVERSITY,OH,"$33,366"
Ovarian Cancer,2017,NCI,5U54CA163069-07,6965,Roles of proinflammatory chemokines linking obesity and ovarian cancer,"SON, DEOK-SOO",MEHARRY MEDICAL COLLEGE,TN,"$80,108"
Ovarian Cancer,2017,NCI,5U54CA163072-08,6543,Roles of proinflammatory chemokines linking obesity and ovarian cancer,"BEEGHLY-FADIEL, ALICIA",VANDERBILT UNIVERSITY MEDICAL CENTER,TN,"$18,696"
Ovarian Cancer,2017,NCI,5U24CA210955-02,,PNNL Proteome Characterization Center,"LIU, TAO",BATTELLE PACIFIC NORTHWEST LABORATORIES,WA,"$1,091,415"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5104,Administrative Core,"BAST, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$157,400"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5105,Core 1: Pathology Core,"BROADDUS, RUSSELL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$216,576"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5106,Core 2: Bioinformatics and Biostatistics Core,"BAGGERLY, KEITH",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$165,080"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5107,Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma,"MILLS, GORDON",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$351,522"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5109,Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer,"COLEMAN, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$351,941"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5110,Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP,"BAST, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$338,337"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5111,Developmental Research Program,"SOOD, ANIL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$76,000"
Ovarian Cancer,2017,NCI,1P50CA217685-01,5112,Career Enhancement Program,"SOOD, ANIL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$76,000"
Ovarian Cancer,2017,NCI,5U54CA163066-07,6613,Roles of proinflammatory chemokines linking obesity and ovarian cancer,"WHALEN, MARGARET",TENNESSEE STATE UNIVERSITY,TN,"$15,517"
Ovarian Cancer,2017,NIBIB,5R01EB022033-02,,Engineering an immuno-isolating hydrogel for restoring ovarian endocrine function,"SHIKANOV, ARIELLA",UNIVERSITY OF MICHIGAN,MI,"$374,475"
Ovarian Cancer,2017,NCI,1R25CA217723-01,,Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support,"GRAVES, KRISTI",GEORGETOWN UNIVERSITY,DC,"$320,201"
Ovarian Cancer,2017,NCI,1U01CA217842-01,,Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer,"MILLS, GORDON",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$739,551"
Ovarian Cancer,2017,NIBIB,1R21EB024874-01,,Protein/Polymer Devices for Slow-Release of Immunotherapies to Treat Ovarian Cancer,"POKORSKI, JONATHAN",CASE WESTERN RESERVE UNIVERSITY,OH,"$195,019"
Ovarian Cancer,2017,NCI,5P30CA015704-42,5446,Research Program: Women's Cancer,"PORTER, PEGGY",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$103,290"
Ovarian Cancer,2017,NCI,1K01CA218305-01,,The Impact of Maternal Obesity on the Reprogramming of the Metastatic Microenvironment,"HILLIARD, TYVETTE",UNIVERSITY OF NOTRE DAME,IN,"$103,375"
Ovarian Cancer,2017,NCI,1K99CA218681-01,,The Role of Inflammation in the Racial Disparities in Ovarian Cancer Survival,"PERES, LAUREN",UNIVERSITY OF VIRGINIA,VA,"$94,684"
Ovarian Cancer,2017,NCI,1R21CA220078-01,,The Role of Splice Quantitative Traits in Ovarian Cancer Pathogenesis,"LAWRENSON, KATE",CEDARS-SINAI MEDICAL CENTER,CA,"$235,553"
Ovarian Cancer,2017,NCI,3U54CA096300-15S1,,UPRCCC/MDACC: Partnership for Excellence in Cancer Research (1 of 2),"LOPEZ-BERESTEIN, GABRIEL",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$72,364"
Ovarian Cancer,2017,NCI,3R01CA135354-07S1,,ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer,"BAST, ROBERT",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$99,082"
Ovarian Cancer,2017,NCI,3P50CA159981-05S1,,RPCI-UPCI Ovarian Cancer SPORE,"ODUNSI, KUNLE",ROSWELL PARK CANCER INSTITUTE CORP,NY,"$54,957"
Ovarian Cancer,2017,NCI,3UM1CA173642-05S1,,Women's Health Initiative Cancer Survivor Cohort,"ANDERSON, GARNET",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$56,922"
Ovarian Cancer,2017,NCI,3UM1CA173642-05S2,,Women's Health Initiative Cancer Survivor Cohort,"ANDERSON, GARNET",FRED HUTCHINSON CANCER RESEARCH CENTER,WA,"$165,708"
Ovarian Cancer,2017,NCI,5F31CA203476-02,,A Multimodal Imaging Strategy for Preclinical Optimization of Anticancer Nanomedicines,"RADFORD, DAVID",UNIVERSITY OF UTAH,UT,"$34,742"
Ovarian Cancer,2017,NCI,1R01CA207365-01A1,,Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers,"REBBECK, TIMOTHY",DANA-FARBER CANCER INST,MA,"$732,317"
Ovarian Cancer,2017,NCI,1R01CA211975-01A1,,Cell Cycle Blockade and Therapeutic Sensitization,"SIDDIK, ZAHID",UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,"$366,000"
Ovarian Cancer,2017,NCI,1R01CA211916-01A1,,Nicotinamide N-Methyltransferase (NNMT) as a master regulator of cancer stroma,"LENGYEL, ERNST",UNIVERSITY OF CHICAGO,IL,"$431,980"
Ovarian Cancer,2017,NIGMS,2R01GM088055-18,,Expanding Roles of E2 and E3 Enzymes in Ubiquitin Transfer,"KLEVIT, RACHEL",UNIVERSITY OF WASHINGTON,WA,"$552,327"
Ovarian Cancer,2017,NCI,1R01CA207768-01A1,,Role of MAST1 kinase in cisplatin resistant cancers,"KANG, SUMIN",EMORY UNIVERSITY,GA,"$356,850"
Ovarian Cancer,2017,NCI,1R01CA196988-01A1,,Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer,"ANTALIS, TONI",UNIVERSITY OF MARYLAND BALTIMORE,MD,"$353,419"
Ovarian Cancer,2017,NCI,1R01CA213119-01A1,,Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer,"KASAHARA, NORIYUKI",UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,FL,"$504,040"
Ovarian Cancer,2017,NCI,4R00CA194309-03,,Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer,"AIRD, KATHERINE",PENNSYLVANIA STATE UNIV HERSHEY MED CTR,PA,"$249,000"
Ovarian Cancer,2017,NCI,1R01CA220468-01,,Organic nanoparticles for dual MRI-guided therapeutic selection and ovarian cancer drug delivery,"JOHNSON, JEREMIAH",MASSACHUSETTS INSTITUTE OF TECHNOLOGY,MA,"$538,985"
Ovarian Cancer,2017,NCI,2R01CA160331-06A1,,Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer,"ZHANG, RUGANG",WISTAR INSTITUTE,PA,"$423,225"
Ovarian Cancer,2017,NINR,1R21NR016905-01A1,,Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer,"HURTADO DE MENDOZA CASAUS, ALEJANDRA",GEORGETOWN UNIVERSITY,DC,"$223,567"
Ovarian Cancer,2017,NCI,2R01CA163377-06A1,,Targeting EZH2 in CARM1-expressing epithelial ovarian cancer,"ZHANG, RUGANG",WISTAR INSTITUTE,PA,"$406,125"
Ovarian Cancer,2017,NCI,1F32CA221093-01,,An in vivo model for CCNE1 amplified tumorigenesis,"KROEGER, PAUL",UNIVERSITY OF PENNSYLVANIA,PA,"$60,990"
Ovarian Cancer,2017,NCI,1R01CA214799-01A1,,Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers,"JOHNSON, NEIL",RESEARCH INST OF FOX CHASE CAN CTR,PA,"$418,613"
Ovarian Cancer,2017,NCI,4R00CA194318-03,,Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancer,"BITLER, BENJAMIN",UNIVERSITY OF COLORADO DENVER,CO,"$248,999"
Ovarian Cancer,2017,NCI,1R44CA221426-01,,Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing,"WILLIAMS, LINDSEY","TWINSTRAND BIOSCIENCES, INC.",WA,"$295,409"
Ovarian Cancer,2017,NCI,1R43CA221477-01,,A Novel Agent for Ovarian Cancer,"XIE, GANG","MEDICON, INC.",NY,"$300,000"
Ovarian Cancer,2017,NCI,1R41CA217383-01A1,,Robust Predictor of Breast Cancer Risk,"OSTRER, HARRY","MORGAN AND MENDEL GENOMICS, INC.",DE,"$300,000"
Ovarian Cancer,2017,NCI,2R44CA192569-02,,Tumor-Specific Fluorescent Cocktail Enables Image-Guided Cytoreductive Surgery,"KULARATNE, SUMITH","ON TARGET LABORATORIES, LLC",IL,"$1,250,146"
Ovarian Cancer,2017,NCI,2U54CA163068-06,5836,Adrenergic modulation of ovarian cancer progression and chemoresistance,"MONTEIRO, ALVARO",H. LEE MOFFITT CANCER CTR & RES INST,FL,"$79,503"
Ovarian Cancer,2017,NCI,2U54CA163071-06,5955,Adrenergic modulation of ovarian cancer progression and chemoresistance,"ARMAIZ-PENA, GUILLERMO",PONCE SCHOOL OF MEDICINE,PR,"$69,064"
Ovarian Cancer,2017,NCI,3R01CA188571-03S1,,"DYRK1A signaling in control of cell growth, proliferation and DNA damage repair","LITOVCHICK, LARISA",VIRGINIA COMMONWEALTH UNIVERSITY,VA,"$44,563"
Ovarian Cancer,2017,NCI,261200800001E-111-0-36,,Repository Services for epidemiology studies,"HEIMBROOK, DAVID","LEIDOS BIOMEDICAL RESEARCH, INC.",MD,"$1,380,084"
Ovarian Cancer,2017,NCI,261200800001E-111-0-102,,Biospecimen Collection Proteomic,"HEIMBROOK, DAVID","LEIDOS BIOMEDICAL RESEARCH, INC.",MD,"$6,467,562"
Ovarian Cancer,2017,NCI,3R15CA161970-01S1,,Development of aptamer-based detection and therapy strategies for ovarian cancer,"WHELAN, REBECCA",OBERLIN COLLEGE,OH,"$37,041"
Ovarian Cancer,2017,NCI,1F99CA222541-01,,Manipulation of three-dimensional chromatin structure to regulate oncogenes in breast and ovarian cancer.,"MORGAN, STEFANIE",STANFORD UNIVERSITY,CA,"$45,544"
Ovarian Cancer,2017,NIMHD,2U54MD007600-31,5317,Upstream Regulation and Downstream effectors of c-MYC in Ovarian Cancer,"VIVAS-MEJIA, PABLO",UNIVERSITY OF PUERTO RICO MED SCIENCES,PR,"$340,484"
Ovarian Cancer,2017,NCI,3R43CA195841-01A1S1,,Isothermal Chain Reaction (ICR) Detection of SNP Biomarkers for Ovarian Cancer Pont-of-Care Testing and Risk Stratification,"MANCEBO, RICARDO","GENENDEAVOR, LLC",CA,"$50,000"
Ovarian Cancer,2017,NCI,3R01CA136512-07S1,,BRCA1 Function in Post-Damage Nuclear Foci,"LIVINGSTON, DAVID",DANA-FARBER CANCER INST,MA,"$33,820"
Ovarian Cancer,2017,NCI,3R01CA186700-03S1,,Study of biomarkers in ovarian cancer: modulation by activity & diet intervention,"THOMSON, CYNTHIA",UNIVERSITY OF ARIZONA,AZ,"$35,829"
Ovarian Cancer,2017,NCI,1R43CA213766-01A1,,Novel Glyco-tests to Predict Chemoresistance,"RAZI, NAHID","ACCUDAVA, INC.",CA,"$297,480"
Ovarian Cancer,2017,NCI,3R01CA195670-03S1,,The Tumor Suppressor Role of SMARCA4 in SCCOHT,"WEISSMAN, BERNARD",UNIV OF NORTH CAROLINA CHAPEL HILL,NC,"$81,362"
Ovarian Cancer,2017,NCI,7R01CA197976-03,,The Hippo/Yap Signaling Pathway In Ovarian High Grade Serous Carcinoma,"WANG, CHENG",MASSACHUSETTS GENERAL HOSPITAL,MA,"$294,808"
Ovarian Cancer,2017,NCI,3R01GM111093-03S1,,Glycosylation-dependent mechanisms regulating ovarian tumor cell survival,"BELLIS, SUSAN",UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,"$36,115"
Ovarian Cancer,2017,NCI,261201300008I-2-26100010-1,,SUPPORT SERVICES FOR THE PLCO ETIOLOGIC & EARLY MARKER STUDIES(PLCO EEMS),"RILEY, TOM","INFORMATION MANAGEMENT SERVICES, INC.",MD,"$894,589"
Ovarian Cancer,2017,NCI,1ZIACP010123-22,,Occupational and Environmental Determinants of Cancer among Women and Minorities,"BEANE FREEMAN, LAURA",NIH,,"$352,884"
Ovarian Cancer,2017,NCI,1ZIACP010126-22,,Hormone-Related Cancers,"GIERACH, GRETCHEN",NIH,,"$3,383,977"
Ovarian Cancer,2017,NCI,1ZIACP010128-22,,Therapeutic and Diagnostic Factors as Related to Cancer Risk,"TRABERT, BRITTON",NIH,,"$516,496"
Ovarian Cancer,2017,NCI,1ZIACP010142-19,,Genetic Modifiers of Cancer Risk,"SAVAGE, SHARON",NIH,,"$445,441"
Ovarian Cancer,2017,NCI,1ZIACP010144-19,,Clinical Genetic Studies of Familial and Hereditary Cancer Syndromes,"PEMOV, ALEXANDER",NIH,,"$9,903,769"
Ovarian Cancer,2017,NCI,1ZIACP010145-18,,Intervention Trials in Persons at Increased Genetic Risk of Cancer,"SAVAGE, SHARON",NIH,,"$332,906"
Ovarian Cancer,2017,NCI,1ZIACP010152-18,,PLCO Trial Etiologic and Early Marker Study,"HOOVER, ROBERT",NIH,,"$736,077"
Ovarian Cancer,2017,NCI,1ZIACP010169-16,,"Nutrition, Metabolism, and Cancer","ZIEGLER, REGINA",NIH,,"$356,089"
Ovarian Cancer,2017,NCI,1ZIACP010182-15,,Epidemiologic Field Studies,"SCHAIRER, CATHERINE",NIH,,"$767,797"
Ovarian Cancer,2017,NCI,1ZIACP010187-13,,Cancer Genetic Markers of Susceptibility,"HOOVER, ROBERT",NIH,,"$106,767"
Ovarian Cancer,2017,NCI,1ZIACP010200-10,,GEI - Genome-Wide Association Studies,"CAPORASO, NEIL",NIH,,"$162,269"
Ovarian Cancer,2017,NCI,1ZIACP010207-08,,PLCO EEMS and Extended Follow Up,"HOOVER, ROBERT",NIH,,"$800,895"
Ovarian Cancer,2017,NIEHS,1ZIAES049033-21,,Genetic Susceptibility And The Environment In Cancer Risk,"TAYLOR, JACK",NIH,,"$316,807"
Ovarian Cancer,2017,NICHD,1ZIAHD008804-11,,The Role of Carboxypeptidase E in Cancer,"LOH, YOKE PENG",NIH,,"$428,245"
Ovarian Cancer,2017,NCATS,1ZIATR000075-03,,High Content Screening using 3-D Models of Ovarian Cancer,"FERRER-ALEGRE, MARC",NIH,,"$44,666"
Ovarian Cancer,2017,NCATS,1ZIATR000251-02,,qHTS to Identify Inhibitors of NNMT1,"HALL, MATTHEW",NIH,,"$44,666"
Ovarian Cancer,2017,NCATS,1ZIATR000268-02,,3D Bioprinting of human native-like tissues as disease-in-a-dish models for drug discovery,"FERRER-ALEGRE, MARC",NIH,,"$1,618,900"
Ovarian Cancer,2017,NCI,ACN15006001-1-0-1,,NCI Early Detection Research Network:  Biomarker Reference and Resource Center (BRRC),NO PI IDENTIFIED,NIH,,"$800,000"
Ovarian Cancer,2017,NCI,1ZIABC005598-28,,Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells,"GOTTESMAN, MICHAEL",NIH,,"$818,215"
Ovarian Cancer,2017,NCI,1ZIABC006161-34,,DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs,"POMMIER, YVES",NIH,,"$1,021,151"
Ovarian Cancer,2017,NCI,1ZIABC009052-28,,Papillomavirus Virion Proteins and Vaccines,"SCHILLER, JOHN",NIH,,"$754,757"
Ovarian Cancer,2017,NCI,1ZIABC010298-20,,Growth Regulation Section,"PASTAN, IRA",NIH,,"$427,052"
Ovarian Cancer,2017,NCI,1ZIABC010657-13,,Cellular In vivo Imaging,"CHOYKE, PETER",NIH,,"$1,019,348"
Ovarian Cancer,2017,NCI,1ZIABC010661-13,,Vaccine and Drug Combination Therapy for Human Cancers,"HODGE, JAMES",NIH,,"$648,692"
Ovarian Cancer,2017,NCI,1ZIABC010830-11,,Mechanisms of non-classical multidrug resistance in cancer,"GOTTESMAN, MICHAEL",NIH,,"$1,402,654"
Ovarian Cancer,2017,NCI,1ZIABC011054-10,,Nuclear Factor-kappaB in Ovarian Cancer,"ANNUNZIATA, CHRISTINA",NIH,,"$717,308"
Ovarian Cancer,2017,NCI,1ZIABC011311-08,,Identification of genetic interactors of Brca2,"SHARAN, SHYAM",NIH,,"$1,029,736"
Ovarian Cancer,2017,NCI,1ZIABC011525-05,,Leveraging DNA damage repair pathways as therapeutic targets in womens cancers,"LEE, JUNG-MIN",NIH,,"$745,273"
Ovarian Cancer,2017,NCI,1ZIABC011584-04,,Clinical trials in womens cancers,"ANNUNZIATA, CHRISTINA",NIH,,"$286,923"
Ovarian Cancer,2017,NCI,1ZIABC011737-02,,Therapeutic evaluation in ovarian and breast cancer GEMGDA models,"SHARAN, SHYAM",NIH,,"$1,283,220"
Ovarian Cancer,2017,NCI,1ZIABC011775-01,,Immune cell control of ovarian cancer,"ANNUNZIATA, CHRISTINA",NIH,,"$430,385"
Ovarian Cancer,2017,NCI,1ZIASC006353-35,,Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy,"BRECHBIEL, MARTIN",NIH,,"$926,927"
Ovarian Cancer,2017,NHGRI,1ZIAHG000120-21,,The role of the BRCA1 and BRCA2 gene in the pathogenesis of breast cancer,"BRODY, LAWRENCE",NIH,,"$39,630"
Ovarian Cancer,2017,NHGRI,1ZIAHG200323-13,,"Genomic, Epigenetic and Functional Analyses of Vertebrate Regulatory Regions","ELNITSKI, LAURA",NIH,,"$1,748,348"
